Invivyd (IVVD) said Monday virology data supports its assertion its half-life extended investigational monoclonal antibody PEMGARDA, or pemivibart, is effective against current SARS-CoV-2 variant spike proteins.
Invivyd collaborates with LabCorp's Monogram Biosciences to monitor antiviral activity for independent virology assessments, and to deterime if its pemivibart potency needs to be changed as SARS-CoV-2 variants evolve.
Shares of the company were up 2.5% in recent Monday premarket activity.
Price: 1.2300, Change: +0.03, Percent Change: +2.50
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.